Harley-Davidson Inc. (NYSE: HOG) $28.35 +6.98% Harley-Davidson shares up on buyout rumor (NYSE:HOG), ($HOG)

eOn Communications Corp. (NASDAQ: EONC) $3.62 -21.81% eOn Communications shares fall despite report of 169% increase in quarterly revenue (NASDAQ:EONC), ($EONC)

Republic First Bancorp Inc. (NASDAQ: FRBK) $3.22 -26.82% Metro Bancorp and Republic First Bancorp cancel takeover deal (NASDAQ:FRBK), ($FRBK)

Discover Financial Services (NYSE: DFS) $15.30 +0.66% Discover Financial Services post Q1 loss on higher reserves; to repay TARP (NYSE:DFS), ($DFS)

Intel Corp. (NASDAQ: INTC) $22.01 +3.97% Intel shares rise on new processor launch (NASDAQ:INTC), ($INTC)

Limited Brands Inc. (NYSE: LTD) $24.71 +4.22% Limited Brands board declares special dividend of $1 a share, authorizes $200 million stock-repurchase program (NYSE:LTD), ($LTD)

Wal-Mart Stores Inc. (NYSE: WMT) $55.99 +1.03% Wal-Mart plans expansion into 500 more stores (NYSE:WMT), ($WMT)

Boston Scientific Corp. (NYSE: BSX) $7.09 +4.26% Boston Scientific shares rise after device meets goal in study (NYSE:BSX), ($BSX)

JetBlue Airways Corp. (NASDAQ: JBLU) $5.42 -0.55% JetBlue Airways reports 2.7% increase in February traffic (NASDAQ:JBLU), ($JBLU)

Advanced Micro Devices Inc. (NYSE: AMD) $9.40 +5.38% Advanced Micro Devices to roll out it new line of server chips later this month (NYSE:AMD), ($AMD)

Thresher Industries Inc. (OTC: THRR) $0.0027 +350.00% THRR approves sale of the company; up on unusual volume (OTC:THRR) ($THRR)

Telanetix Inc. (OTC:TNXI) $0.0850 +102.38% Telanetix swings to Q4 profit (OTC:TNXI), ($TNXI)

Imaging Diagnostic Systems Inc. (OTC: IMDS) $0.0595 +65.28% Imaging Diagnostic Systems says it exhibited its CT Laser Mammography (CTLM) system at the 2010 European College of Radiology (OTC:IMDS), ($IMDS)

Golden Eagle International Inc. (OTC: MYNG) $0.0011 +22.22% Golden Eagle transfers control of its Bolivian subsidiary operations (OTC:MYNG), ($MYNG)

Prime Star Group Inc. (OTC: PSGI) $0.0520 +6.12% Prime Star Group announces $16 million distribution agreement (OTC:PSGI), ($PSGI)

PlanGraphics Inc. (OTC: PGRA) $0.0070 +16.67% PlanGraphics signs letter of intent to acquire All-Star Transportation (OTC:PGRA), ($PGRA)

Cyberlux Corp. (OTC: CYBL) $0.0001 -50.00% (OTC:CYBL), ($CYBL)

Vycor Medical Inc. (OTC: VYCO) $0.0650 +30.00% Vycor Medical says it has started SFDA registration process to market ViewSite Brain Access System (VBAS) in China (OTC:VYCO), ($VYCO)

Ecosphere Technologies Inc. (OTC: ESPH) $1.24 +12.79% Ecosphere Technologies announces the U.S. PTO issued formal Notice of Allowance for two of its patents to treat industrial wastewaters and potable waters (OTC:ESPH), ($ESPH)

iSecureTrac Corp. (OTC: ISEC) $0.690 +25.45% iSecureTrac says company was positive cash in 2009 (OTC:ISEC), ($ISEC)

IDO Security Inc. (OTC: IDOI) $0.0030 — IDO Security invited by Lotan Security to participate in an “invitation only” seminar focusing on new technologies for airport security (OTC:IDOI), ($IDOI)

Biolase Technology Inc. (NASDAQ: BLTI) $2.25 +21.62% Biolase Technology announces 501(k) clearance from U.S. FDA for iLase diode laser (NASDAQ:BLTI), ($BLTI)

FactSet Research Systems Inc. (NYSE: FDS) $73.09 +2.05% FactSet Research Systems posts higher quarterly profit (NYSE:FDS), ($FDS)

Icagen Inc. (NASDAQ: ICGN) $0.73 +34.95% Icagen shares rise after reporting positive results in its Phase IIa epilepsy study of ICA-105665 (NASDAQ:ICGN), ($ICGN)

Bank of America Corp. (NYSE: BAC) $17.02 +1.01% Investors shifting focus away from Europe and into the U.S. and Japan.-BofA Merrill Lynch Survey of Fund Managers for March (NYSE:BAC), (NYSE:BAC)

Google Inc. (NASDAQ: GOOG) $568.39 +0.93% Nexus One sales moving at slow pace-report (NASDAQ:GOOG), ($GOOG)

American Dairy Inc. (NYSE: ADY) $19.58 -2.68% American Dairy falls after wider-than expected loss (NYSE:ADY), (NYSE:ADY)

DSW Inc. (NYSE: DSW) $26.82 -8.89% DSW swings to Q4 profit, sales surpass estimates (NYSE:DSW), ($DSW)

BioTime Inc. (AMEX: BTIM) $7.63 +31.55% BioTime announces publication of reversal of developmental aging of normal cells (AMEX:BTIM), ($BTIM)

Yahoo! Inc. (NASDAQ: YHOO) $16.34 -0.73% Yahoo likely to acquire Citizen Sports-report (NASDAQ:YHOO), ($YHOO)

General Electric Company (NYSE: GE) $17.69 +2.31% GE CFO says company sees profit and dividend hike in 2011 (NYSE:GE), ($GE)

by Eric Ryan, Beacon Contributing Writer

Intellipharmaceutics International Inc. (IPCI) engages in the research, development and commercialization of controlled-release drug technologies. The Company has 15 drug programs in development that address various therapeutic areas, including neurology, cardiovascular, Gastro-Intestinal Tract (GIT), pain and infection. Partnered with Par Pharmaceutical Companies Inc. (NYSE: PRX), the Company’s lead drug product, a generic form of Focalin XR, is under review by the Food and Drug Administration for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Another one of the Company’s leading drug candidate is Rexista, a competing drug to Oxycodone, developed to alleviate pain.

Founded in 2009, the Company is headquartered in Toronto, Canada.

Source: Reuters.com, SEC Filings.

Financial Summary

Source: Reuters.com, SEC Filings.

Analyst Consensus

No analyst rates shares of IPCI at this time.

Investment Highlights

ICPI engages in the research, development and commercialization of controlled-release drug technologies. The Company has 15 drug programs in development, which address various therapeutic areas, including neurology, cardiovascular, Gastro-Intestinal Tract (GIT), pain and infection. Partnered with Par Pharmaceutical Companies Inc. (NYSE: PRX), the Company’s lead drug product, a generic form of Focalin XR, is under review by the Food and Drug Administration for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Another one of the Company’s leading drug candidate is Rexista, a competing drug to Oxycodone, developed to alleviate pain.

With the development of its four leading drug products, including Generic Focalin XR, Generic Effexor XR, Rexista (Oxycodone) and Generic Coreg CR, the Company attempts to capture a portion of a combined market of more than $6.0 billion in annual revenue. Presently, revenue derived from its competitors’ proprietary drugs Focalin XR, Effexor XR, Coreg CR and Oxycodone RX total $350 million, $3.9 billion, $300 million and $2.0 billion, respectively.

The novel approach of manipulating the delivery of the above-named drug therapies via the Company’s novel Hypermatrix(TM) concept allows the Company a margin of competitive advantage within the pharmaceutical space. Its Hypermatrix delivery system concept is designed to optimize Nature’s hyper-dimensionality as it relates to drug therapies.

Focusing on manipulation of the hyper-dimensionality variables of “Time” and “Space” of dosages are believed to enhance efficacy of present drug therapies void of these variable considerations during the course of treatment, especially, for example, in the treatments relating to the Gastro-Intestinal Tract (GIT), where the time release and volume of dosages have shown to improve efficacy of the drug’s intended effects.

In a recent news release, the Company delineated the five desired achievements of its Hypermatrix delivery platform, which include “Spatial Recognition and Control of the optimum GIT site for drug release; Defensive Control over adverse factors such as food effects or excess acidity; Temporal Control over the time when drug release commences or ends; Structural Control over the physical characteristics of the solid dosage form from ingestion to full release; Rate Control over the entire release profile to deliver true intelligent extended release.”

Latest Company News

On March 11, 2010, the Company announced that patent suits filed against Novartis Pharmaceuticals Corp., Celgene Corp. and Elan Pharma International Ltd. have been settled. Suits were settled in U.S. District Court for the District of New Jersey in the cases against Novartis Pharmaceuticals Corp. and Celgene Corp., and in the U.S. District Court for the District of Delaware in the case against Elan Pharma International Ltd. over Generic Focalin XR(R), a generic version of a drug treatment for alleviating patients suffering of Attention Deficit Hyperactivity Disorder.

Terms of the settlements were not disclosed, remaining confidential and subject to regulatory as well as court approval.

Technical Analysis

i

Source: http://stockcharts.com/h-sc/ui?s=IPCI

IPCI trades above its 13-day moving average. This bullish sign is significant because the moving average is positively trending.

The MACD for IPCI currently indicates a bullish signal. In addition, the MACD is above the signal line, a 9-day moving average of the MACD. The MACD is also above the critical level of 0, which implies the past price action had been positive. Overall, the chart is bullish.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

Source: Yahoo Finance

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

]]> http://www.beaconequity.com/stock-alert-for-intellipharmaceutics-international-incorporated-ipci/feed/ 0 http://www.beaconequity.com/stock-alert-for-stemcells-inc-stem-3/ http://www.beaconequity.com/stock-alert-for-stemcells-inc-stem-3/#comments Tue, 16 Mar 2010 07:41:53 +0000 BeaconEquity.com http://www.beaconequity.com/?p=7991 StemCells Inc. (NASDAQ: STEM)

by Dominique Salto, Beacon Contributing Writer

StemCells Inc. (STEM) is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell, and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the U.S. Food and Drug Administration (FDA) to initiate a phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

The Company was founded in 1988 and is based in Palo Alto, California.

Source: Reuters.com, SEC Filings.

Financial Summary

For the fourth quarter of 2009, the Company reported a net loss of $5,234,000, or $(0.05) per share, compared with a net loss of $10,082,000, or $(0.11) per share, for the fourth quarter of 2008. Loss from operations was $8,081,000, compared to $7,098,000 for the same period of 2008. Total revenue was $418,000, compared to $172,000 for the same period of 2008. The growth in revenue in the fourth quarter of 2009 compared to the same period of 2008 was primarily due to the consolidation of the SCS operations, which included the addition of product sales revenue from the Company’s SC Proven ® portfolio of specialty cell culture products.

For the full year 2009, the Company reported a net loss of $27,026,000, or $(0.25) per share, compared with a net loss of $29,087,000, or $(0.35) per share, for 2008. Loss from operations was $29,378,000, compared to $26,738,000 for 2008. Total revenue was $993,000, a 328% increase over total revenue of $232,000 reported in 2008. This increase was primarily due to the SCS operations, which included a total of $385,000 in product sales from the SC Proven business for the period April 1 to December 31, 2009.

Total operating expenses in 2009 were $30,110,000, compared to $26,970,000 in 2008. Approximately 80%, or $2,537,000, of the increase in 2009 was due to the SCS operations. Operating expenses in 2009 also included two non-recurring items: (i) transaction expenses of $693,000 related to the SCS acquisition, and (ii) a charge of $310,000 to set up a reserve for expenses associated with the Company’s exit from its Melbourne, Australia site. Excluding these non-recurring items and the expenses associated with the SCS operations, operating expenses were essentially unchanged compared to 2008.

For the full year 2009, the Company recorded other income of $1,899,000 due to a decrease in warrant liability, while in 2008 the Company recorded a charge of $937,000 to reflect an increase in warrant liability. In 2008, the Company also recorded a charge of $2,083,000 to write down the value of its investment in marketable equity securities. There was no such write down in 2009.

For the full year 2009, cash used in operations totaled $24,683,000, compared to $22,740,000 in 2008. At December 31, 2009, the Company’s cash, cash equivalents and marketable debt securities totaled $38,618,000.

Source: Reuters.com, SEC Filings.

Analyst Consensus

This is the consensus forecast amongst 1 polled investment analysts. Against the StemCells Inc company.

The one analyst offering a 12-month price target expects STEM share price to rise to 3.00 in the next year from the last price of 1.19.

Source: www.ft.com

Consensus Estimates Analysis

Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=STEM.W

Investment Highlights

STEM recently posted its fourth-quarter results, gaining revenue from its acquisition of Stem Cell Sciences PLC in April in a cash and stock deal. In the fourth quarter, STEM said it lost $5.2 million, or $(0.05) per share. A year ago, the Company posted a loss of $10.1 million, or $(0.11) per share. Its revenue more than doubled to $418,000 from $172,000.

Revenue from licensing agreements and grants more than doubled to $308,000 as the Company entered new partnerships; the Stem Cell Sciences acquisition gave STEM $1.1 million in product sales. It had none last year.

In February the Company announced the launch of GS2-M(TM), a new cell culture medium that enables the derivation and long-term maintenance of true (germline competent) mouse induced pluripotent stem (iPS) cells. GS2-M is part of the Company’s growing SC Proven^(R) line of specialty cell culture products; GS-2 M has been shown to increase the efficiency of reprogramming ‘pre-iPS’ cells to derive fully pluripotent stem cells, and to maintain mouse iPS cells in a definitive pluripotent state in long-term culture.

The majority of preclinical iPS cell research being done today involves the use of mouse cells. For this reason, the Company said GS2-M is expected to be of significant interest to scientists in the expanding field of iPS cell research.

STEM’s HuCNS-SC may be able to replace acetylcholine-producing nerve cells in Alzheimer’s disease, restore lost motor neurons in ALS (amyotropic lateral sclerosis, also known as Lou Gehrig’s disease), or produce inhibitory cells to help block inappropriate electrical activity in epilepsy patients.

In addition to the potential of the human neural stem cells in transplant-based therapies, STEM envisions many other uses of its cells:

To help identify and characterize factors that affect the nerve supply and modulators of such factors.

To express unique molecules and signaling pathways that could serve as targets for new drugs.

Cultured neural stem cells can be induced to differentiate (specialize) into various types of neural cells (e.g., neurons, astrocytes, oligodendrocytes) that may prove useful in drug-discovery efforts, for instance:

• Neural stem cells or differentiated cells derived from them may be used to evaluate the biologic effect (pharmacology) and possible toxic effects (toxicology) of drugs, thus reducing the use of animal testing and making animal and human testing safer.
• High-throughput screening can be conducted on drug libraries with human neural stem cells to learn what effects drugs have on cell differentiation pathways.
• Neural stem cells may be used for gene-expression profiling to discover rare genes that are only expressed in stem cells and to examine gene expression when stem cells are exposed to various stimuli, including CNS-acting drugs.

Source: http://www.stemcellsinc.com/

Technical Analysis

Source: http://stockcharts.com

STEM is below its 50-day moving average. This bearish sign is even more significant because the moving average is also trending lower.

STEM has been relatively stable recently. This is evidenced by the width of its Bollinger Bands, which are tighter than normal. Additionally, STEM is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

STEM’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

Source: Yahoo Finance

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

]]> http://www.beaconequity.com/stock-alert-for-stemcells-inc-stem-3/feed/ 0 http://www.beaconequity.com/pepsico-inc-nyse-pep-66-15-1-61-pepsico-announces-15-billion-stock-buy-back-shares-jump-nysepep-pep/ http://www.beaconequity.com/pepsico-inc-nyse-pep-66-15-1-61-pepsico-announces-15-billion-stock-buy-back-shares-jump-nysepep-pep/#comments Mon, 15 Mar 2010 22:54:16 +0000 BeaconEquity.com http://www.beaconequity.com/?p=8001 PepsiCo Inc. (NYSE: PEP) $66.15 +1.61% PepsiCo announces $15 billion stock buy back, shares jump (NYSE:PEP), ($PEP)

American International Group Inc. (NYSE: AIG) $34.32 +0.26% AIG raises $452 million through sale of Transatlantic shares (NYSE:AIG), ($AIG)

Gramercy Capital Corp. (NYSE: GKK) $2.50 -40.48% Gramercy reports FFO fell to a loss of $71.8 million, versus positive FFO of $35.9 million a year ago (NYSE:GKK), ($GKK)

ConocoPhillips (NYSE: COP) $51.65 -0.06% ConocoPhillips subsidiary agrees to pay to $588K to settle 2004 Tacoma oil spill claim (NYSE:COP), ($COP)

Cisco Systems Inc. (NASDAQ: CSCO) $26.08 +0.77% StreetInsider.com: Goldman Sachs raises price targets on networking stocks (NASDAQ:CSCO), ($CSCO)

Nortel Networks Corp. (USA) (OTC: NRTLQ) $0.09 +70.60% NRTLQ moving on above average volume (OTC:NRTLQ), ($NRTLQ)

Research In Motion Limited (USA) (NASDAQ:RIMM) $75.54 +0.27% (NASDAQ:RIMM), ($RIMM)

China Sunergy Co. Ltd. (ADR) (NASDAQ: CSUN) $4.05 -1.46% CSUN to acquire 100% of the shares of two related module manufacturers (NASDAQ:CSUN), ($CSUN)

Medtronic Inc. (NYSE: MDT) $45.81 +4.26% Medtronic announces initial results of STOP AF clinical trial (NYSE:MDT), ($MDT)

Citigroup Inc. (NYSE: C) $3.89 -2.02% StreetInsider.com: Citi issues some data on February credit-card delinquencies and write-offs (NYSE:C), ($C)

Smartlinx Inc. (OTC: SMLK) $0.730 +43.14% Smartlinx signs memorandum of understanding with Nettlinx to collaborate on the development of biometric based eGovernance system (OTC:SMLK), ($SMLK)

KCM Holdings Corp. (OTC: KCMH) $0.0600 — KCM Holdings announces 2010 progress update for its incubation portfolio (OTC:KCMH), ($KCMH)

Dana Resources (OTC: DANR) $0.0310 +11.11% Chota Silver Mine Update (OTC:DANR), ($DANR)

Blast Applications Inc. (OTC: BLAP) $0.0150 +66.67% Blast Applications launches live updating tasks manager system (OTC:BLAP), ($BLAP)

Zevotek Inc. (OTC: ZVTK) $0.0047 +38.24% Zevotek receives $100,000 order to buy Ionic Bulbs for delivery in March 2010 (OTC:ZVTK), ($ZVTK)

Newport Digital Technologies Inc. (OTC: NPDT) $0.0180 -4.26% Former minister of the Ministry of Economic Affairs of Taiwan (MOEA) joins NPDT advisory board (OTC:NPDT), ($NPDT)

Neurologix Inc. (OTC: NRGX) $0.680 +4.62% Neurologix receives Notice of Allowance from the U.S.PTO for epilepsy therapeutic approach (OTC:NRGX), ($NRGX)

Green Oasis Environmental (OTC: GRNO) $0.370 -5.13% Morgan Stanley forecasts 2010 oil to reach $95 per barrel, Company reports (OTC:GRNO), ($GRNO)

Turbodyne Technologies Inc. (OTC:TRBD) $0.0110 +10.00% Volume alert (OTC:TRBD), ($TRBD)

Artfest International Inc. (OTC: ARTS) $0.0050 +38.89% ARTS shareholders of record to receive Artfest Direct dividend valued at $10/share (OTC:ARTS), ($ARTS)